The influence of behavioural heterogeneity on the population level effect of potential prophylactic type 1 human immunodeficiency virus vaccines

Journal of the Royal Statistical Society. Series A: Statistics in Society

Volumn 161, Issue 2, 1998, Pages 209-225

  Garnett, Geoff P ^a,b  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Behavioural heterogeneity; HIV immunization; HIV interventions; HIV vaccine; Human immunodeficiency virus (HIV); Mathematical models

Indexed keywords

EID: 0039988643     PISSN: 09641998     EISSN: None     Source Type: Journal    
DOI: 10.1111/1467-985X.00100     Document Type: Article

References (54)

1. Anderson, R. M. and Garnett, G. P. (1996) Low efficacy HIV vaccines: potential for community-based intervention programmes. Lancet, 348, 1010-1013
2. Anderson, R. M. and May, R. M. (1991) Infectious Diseases of Humans: Dynamics and Control. Oxford: Oxford University Press.
3. Anderson, R. M., May, R. M., Medley, G. F. and Johnson, A. M. (1986) A preliminary study of the transmission dynamics of the human immunodeficiency virus (HIV), the causative agent of AIDS. IMA J. Math. Appl. Med. Biol., 3, 229-263.
4. Anderson, R. M., Swinton, J. and Garnett, G. P. (1995) Potential impact of low efficacy HIV-I vaccines in populations with high rates of infection. Proc. R. Soc. Lond. B, 261, 147-151.
5. Anzala, A. O., Nagelkerke, N. J. D., Bwayo, J., Holton, D., Mosses, S., Ngugi, E. N., Ndinya-Achola, J. O. and Plummer, F. A. (1995) Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection. J. Infect. Dis., 171, 686-689.
6. Asiimwe-Okiror, G., Opio, A. A., Musinguzi, J., Madraa, E., Tembo, G. and Carael, M. (1997) Changes in sexual behaviour and decline in HIV infection among young pregnant women in urban Uganda. AIDS, 11, 1757-1764.
7. Blower, S. M. and McLean, A. R. (1994) Prophylactic vaccines, risk behaviour change and the probability of eradicating HIV in San Francisco. Science, 265, 1451-1454.
8. Burke, D. S. (1995) Human trials of experimental HIV vaccines. AIDS, 9, suppl. A, S171-S180.
9. Carael, M., Cleland, J., Deheneffe, J.-C., Ferry, B. and Ingham, R. (1995) Sexual behaviour in developing countries: implications for HIV control. AIDS, 9, 1171-1176.
10. Chesney, M. A., Lurie, P. and Coates, T. J. (1995) Strategies for addressing the social and behavioural challenges of prophylactic HIV vaccine trials. J. Acq. Immune Def. Synd. Hum. Retro., 9, 30-35.
11. Cohen, J. C. (1997) Planned tests in Thailand spark debate. Science, 176, 1197.
12. Dixon, D. O., Rida, W. N., Fast, P. E. and Hoth, D. F. (1993) HIV vaccine trials: some design issues including sample size calculation. AIDS, 6, 485-496.
13. Esparza, J., Osmanov, S. and Heyward, W. L. (1996) HIV preventive vaccines - progress to date. Drugs, 50, 792-804.
14. Expanded Programme on Immunisation (1995) Statement on poliomyelitis eradication. Wkly Epidem. Rec., 70, 345-347.
15. Fenner, F., Henderson, D. A., Arita, I., Jezek, Z. and Ladayi, I. D. (1988) Smallpox and Its Eradication. Geneva: World Health Organization.
16. Fine, P. E. M. (1993) Herd immunity: history, theory, practice. Epidem. Rev., 15, 265-302.
17. Fleury, B., Janvier, G., Pialoux, G., Buseyne, F., Robertson, M. N., Tartaglia, J., Paoletti, E., Kieny, M. P., Excler, J. L. and Riviere, Y. (1996) Memory cytotoxic T-lymphocyte responses in human immunodeficiency virus type-1 (HIV-1) negative volunteers immunized with a recombinant canarypox expressing gp160 of HIV-1 and boosted with a recombinant gp160. J. Infect. Dis., 174, 734-738.
18. Garnett, G. P. and Anderson, R. M. (1993a) Factors controlling the spread of HIV in heterosexual communities in developing countries: patterns of mixing between different age and sexual activity classes. Phil. Trans. R. Soc. Lond. B, 342, 137-159.
19. _ (1993b) Contact tracing and the estimation of sexual mixing patterns: the epidemiology of gonococcal infections. Sex. Transmttd Dis., 20, 181-191.
20. _ (1994) Balancing sexual partnerships in an age and activity stratified model of HIV transmission in heterosexual populations. IMA J. Math. Appl. Med. Biol., 11, 161-192.
21. _ (1995) Strategies for limiting the spread of HIV in developing countries: conclusions based on studies of the transmission dynamics of the virus. J. AIDS, 9, 500-513.
22. _ (1996) Antiviral therapy and the transmission dynamics of HIV-1. J. Antimicrob. Chemther., 37, suppl. B, 135-150.
23. Ghani, A. C. and Garnett, G. P. (1998) Measuring sexual partner networks for transmission of sexually transmitted diseases. J. R. Statist. Soc. A, 161, 227-238.
24. Girard, M., Yue, L., Barresinoussi, F., Vanderryst, E., Meignier, B., Muchmore, E. and Fultz, P. N. (1996) Failure of human-immunodeficiency virus type-1 (HIV-1) subtype B derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain. J. Virol., 70, 8229-8233.
25. Gregson, S., Garnett, G. P. and Anderson, R. M. (1994) Is HIV-1 likely to become a leading cause of adult mortality in sub-Saharan Africa? J. AIDS, 7, 839-852.
26. Grosskurth, H., Mosha, F., Todd, J., Mwijarubi, E., Klokke, A., Senkoro, K., Mayaud, P., Changalucha, J., Nicoll, A., ka-Gina, G., Newell, J., Mugeye, K., Mabey, D. and Hayes, R. (1995) Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trials. Lancet, 346, 530-536.
27. Halloran, M. E., Longini, I. M., Struchiner, C. J., Haber, M. J. and Brunet, R. C. (1994) Exposure efficacy and change in contact rates in evaluating prophylactic HIV vaccines in the field. Statist. Med., 13, 357-377.
28. Hamer, S. M. (1996) Advances in antiretroviral therapy and viral load monitoring. AIDS, 10, suppl. 3, S1-S11.
29. Hayes, R. J., Schulz, K. F. and Plummer, F. A. (1995) The cofactor effect of genital ulcers on the per exposure risk of HIV transmission in sub-Saharan Africa. J. Trop. Med. Hyg., 98, 1-8.
30. Haynes, B. F. (1993) Scientific and social issues of human immunodeficiency virus vaccine development. Science, 260, 1279-1286.
31. Hethcote, H. W. and Yorke, J. A. (1984) Gonorrhea transmission dynamics and control. Lect. Notes Biomath., 56.
32. Hom, D. L., Johnson, J. L., Mugyenyi, P., Byaruhanga, R., Kityo, C., Loughlin, A., Svilar, G. M., Vjecha, M., Mugerwa, R. D. and Ellner, J. J. (1997) HIV-1 risk and vaccine acceptability in the Ugandan military. J. Acq. Immune Def. Synd. Hum. Retro., 15, 375-380.
33. Jackson, D. J., Martin, Jr, H. L., Bwayo, J. J., Nyange, P. M., Rakwar, J. P., Kashonga, F., Mandaliya, K., Ndinya-Achola, J. O. and Kreiss, J. K. (1995) Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya. AIDS, 9, 1279-1283.
34. Johnson, A. M. and Wadsworth, J. (1994) Heterosexual partnerships. In Sexual Lifestyles and Attitudes (eds A. M. Johnson, J. Wadsworth, K. Wellings and J. Field), pp. 110-182. Oxford: Blackwell Scientific.
35. Koopman, J. and Little, R. J. (1995) Assessing HIV vaccine effects. Am. J. Epidem., 142, 1113-1120.
36. Lawler, A. and Cohen, J. (1997) A deadline for an AIDS vaccine. Science, 176, 1184-1185.
37. Longini, Jr, I. M., Datta, S. and Halloran, M. E. (1996) Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines. J. Acq. Immune Def. Synd. Hum. Retro., 13, 440-447.
38. McLean, A. R. and Blower, S. M. (1993) Imperfect vaccinations and herd immunity to HIV. Proc. R. Soc. Lond. B, 253, 9-13.
39. _ (1995) Modelling HIV vaccination. Trends Microbiol., 3, 458-463.
40. Mertens, T. E., Belsey, E., Stoneburner, R. L., Low Beer, D., Sato, P., Burton, A. and Merson, M. H. (1995) Global estimates and epidemiology of HIV-1 infections and AIDS: further heterogeneity in spread and impact. AIDS, 9, suppl. A, S259-S272.
41. Morgan, D., Malamba, S., Maude, G. H., Okongo, M. J., Wagner, H.-U., Mulder, D. W. and Whitworth, J. A. (1997) An HIV-1 natural history cohort and survival times in rural Uganda. AIDS, 11, 633-640.
42. Mulder, D. W., Nunn, A. J., Kamali, A., Nakiyingi, J., Wagner, H.-U. and Kengenya-Kayondo, J. F. (1994) Two-year HIV-1-associated mortality in Ugandan rural population. Lancet, 343, 1021-1023.
43. Nelson, K. E., Celentano, D. D., Eiumtrakol, S., Hoover, D. R., Beyrer, C., Suprasert, S., Kuntrolbutra, S. and Khamboonrnang, C. (1996) Change in sexual behaviour and a decline in HIV infection among young men in Thailand. New Engl. J. Med., 335, 297-303.
44. Osborn, J. E. (1995) The rocky road to an AIDS vaccine. J. Acq. Immune Def. Synd. Hum. Retro., 9, 26-29.
45. Perelson, A. S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A., Sakasela, K., Markowitz, M. and Ho, D. D. (1997) Decay characteristics of HIV-1-infected compartments during combination therapy. Nature, 387, 188-191.
46. Rida, W. N. (1996) Assessing the effect of HIV vaccination of infectiousness. Statist. Med., 15, 2393-2404.
47. Rida, W., Fast, P., Hoff, R. and Fleming, T. (1997) Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary. J. Acq. Immune Def. Synd. Hum. Retro., 16, 195-203.
48. Rida, W. N. and Lawrence, D. N. (1994) Some statistical issues in HIV vaccine trials. Statist. Med., 13, 2155-2177.
49. Rowland-Jones, S., Sutton, J., Ariyoshi, K., Dong, T., Gotch, F., McAdam, S., Whitby, D., Sabally, S., Gallimore, A., Corrah, T., Takiguchi, M., Schultz, T., McMichael, A. and Whittle, H. (1995) HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat. Med., 1, 59-64.
50. Schultz, A. M. (1994) Obstacles in pursuit of an AIDS vaccine. In HIV Epidemiology, Models and Methods (ed. A. Nicolosi), pp. 175-185, New York: Raven.
51. Smith, C. E. G. (1964) Factors in the transmission of virus infections from animals to man. Scient. Basis Med. A. Rev., 125-150.
52. Thomas, J. C. and Tucker, M. J. (1996) The development and use of the concept of a sexually transmitted disease core. J. Infect. Dis., 174, suppl. 2, S134-S143.
53. Wasserheit, J. N. and Aral, S. O. (1996) The dynamic topology of sexually transmitted disease epidemics: implications for prevention strategies. J. Infect. Dis., 174, suppl. 2, S201-S213.
54. World Health Organization (1995) Scientific and public health rationale for HIV vaccine efficacy trials. AIDS, 9, WHO1-WHO4.